CN101088541A - Medicine for treating women's tumors and malignant tumors and its prepn proces - Google Patents
Medicine for treating women's tumors and malignant tumors and its prepn proces Download PDFInfo
- Publication number
- CN101088541A CN101088541A CN 200710129918 CN200710129918A CN101088541A CN 101088541 A CN101088541 A CN 101088541A CN 200710129918 CN200710129918 CN 200710129918 CN 200710129918 A CN200710129918 A CN 200710129918A CN 101088541 A CN101088541 A CN 101088541A
- Authority
- CN
- China
- Prior art keywords
- medicine
- tumor
- hours
- malignant tumor
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses one kind of medicine for treating women' s tumors and malignant tumors and its preparation process. The medicine is prepared with 15 kinds of Chinese medicinal materials, including motherwort, phellodendron bark, aweto, glossy ganoderma, saffron, etc in certain weight proportion. The medicine has the functions of promoting blood circulation to disperse blood clots, clearing away heat and toxic material, raising immunity, etc.
Description
One, technical field
The present invention relates to a kind of medicine for the treatment of gynecological tumor, malignant tumor and preparation method thereof, more particularly relating to a kind of is the medicine and preparation method thereof of raw material treatment gynecological tumor, malignant tumor with Chinese medicine.
Two, background technology
The traditional Chinese medical science thinks that it is one of main etiology and pathology of malignant tumor that pyretic toxicity pents up.The effect of method of dissipating heat and detoxifying treatment existing direct inhibition of tumor or killing tumor cell can improve body's immunological function again and reaches therapeutic effect, and therefore, method of dissipating heat and detoxifying utilization in the treatment malignant tumor is more.Often will intimately be divided into two classes clinically, i.e. burning hot the and interior life of diseases caused by exogenous pathogenic factor be heat.No matter be the burning hot heresy of diseases caused by exogenous pathogenic factor or other all evil human bodies of invading, give birth to burning hot in can both being converted into.Simultaneously, internal injury caused by excess of seven emotions and visceral dysfunction, also heat-transformation is lit a fire in vivo.Be YANG pathogen, its property is burnt bright, and the easiest impairment of body fluid consumption gas is given birth to pneumatic blood and the cloudy deteriorated blood that burns.Accumulate in the body in the burning hot heresy, the visitor is in flesh and blood, and harmony is poly-does not loose, and the corrosion flesh and blood all can lead to pus of carbuncle, or sends out and be tumor.Excess-fire has significantly burning hot flourishing symptom, and it is not obvious that the moon is hindered symptom, as hyperpyrexia, and thirst and desire for cold drink, the appearance knot is red, and it is red etc. that constipation is urinated; Asthenic fire then based on the moon wound, has deficiency-heat syndrome, as afternoon low grade fever, and dysphoria with feverish sensation in the chest palms and soles, night sweat, dry pharynx, the tip of the tongue is light red etc.Intimately go into blood system, can stagnate in the part, the corrosion flesh and blood is sent out and is the carbuncle skin infection.Penting up the mechanism that causes carcinoma about pyretic toxicity also has a lot of documents to set forth.Clinically see that the carcinoma patient is the disease of heat stagnation fire-toxin more, no matter excess-fire (heat), asthenic fire (heat), all calorific potential sparrow hawks open, and illustrates that tumor develops, and belong to resembling that disease advances, and this moment is at pathogenesis, to the method for this carcinoid tumor patient when plan heat-clearing and toxic substances removing, nourishing YIN to lower pathogenic fire.As many diseases body void of a specified duration, stasis of blood poison caves in, and the state of an illness is turned out cloudy by sun, becomes insidious heresy, then forms the erosion of vulva and dislikes cellulitis, and magic flower festers, granuloma, seepage flow blood and slime.Control insidious heresy, then need the temperature compensation Tuoli, strengthening vital QI to eliminate pathogenic factors is dispeled insidious heresy with QI and blood regulating.
Breast carcinoma, hysteromyoma, ovarian cyst and gynecological cancer card are the benign tumors common among the women, that sickness rate is higher, good sending out in the women between 20-50 year, and sickness rate is up to 20%, and is also in rising trend at present.Clinical symptoms shows as: menstrual cycle shortens, hypervolemia, even big clot is arranged, and menostaxis, part patient is with stomachache, leucorrhoea grow in quantity or concurrent infertile.Bigger as muscular tumor, on the abdominal part pubic symphysis or touch lump, bilanual gynecological examination can touch muscular tumor or cyst enclosed mass, and ultrasound diagnosis also can be used as main diagnosis basis.Hysteromyoma, the ovarian cyst cause of disease still are not sure of at present, it is relevant with the disorder of body inner estrogen that doctor trained in Western medicine is thought, the traditional Chinese medical science is hysteromyoma, ovarian cyst is called " lump in the abdomen ", the result that local vim and vigour retardance is jammed is not only in the formation of lump in the abdomen, and it is relevant closely with the functional disorder of internal organs meridians, modal pathogenesis is that internal injury caused by excess of seven emotions causes the stagnation of QI, or puerperal in menstrual period, deficiency of vital QI, just open the blood chamber, if be affected by the cold, tie in uterus in the blood stasis, or expectorant is turbid, damp and hot, food stagnation all can be tied mutually with QI and blood and cause disease.Though the cause of disease of primary disease has multiterminal, it mainly is qi depression to blood stasis that its pathology develops.For the treatment of primary disease, at present both at home and abroad adopt excisions more, or take tamoxifen (treatment benign tumor medicine), but be not suitable for unmarried or the women of childbearing age is arranged, the clothes Western medicine can cause side effect such as hepatorenal damage and amenorrhea.Treatment has instructive theory " interior warp " upward to say to motherland's medical science for a long time: " hard masses should be resolved gradually, disease with retention of pathogen in the body should be treated by elimination therapy, disease caused by accumulations of pathogen should be treated with therapy of dispersion, diseases with invaded pathogens should be treated by expelling to primary disease." " gynecological through opinion " says: " person that controls the lump in the abdomen transfers basic gas and breaks its blood.”
Three, summary of the invention
One of purpose of the present invention provides a kind of medicine for the treatment of gynecological tumor, malignant tumor.
Two of purpose of the present invention provides a kind of preparation method for the treatment of the medicine of gynecological tumor, malignant tumor.
This and other purpose of the present invention will further embody and set forth by following detailed description and explanation.
The medicine of treatment gynecological tumor of the present invention, malignant tumor is the medicament of being made by the raw material of following weight portion:
Herba Leonuri 10-50 Cortex Phellodendri 10-50 Cordyceps 1-10
Hide Ganoderma 20-60 Stigma Croci 10-50 Rhizoma Smilacis Glabrae 30-60
Herba Scutellariae Barbatae 20-50 Herba Lobeliae Chinensis 20-50 Hedyotidis Diffusae 30-50
Ramulus et folium taxi cuspidatae 20-50 Radix Sophorae Tonkinensis 10-30 Rhizoma Paridis 20-50
CAOHECHE 20-30 Folium Isatidis 20-50 Radix Glycyrrhizae 10-50.
Further, the medicine of treatment gynecological tumor of the present invention, malignant tumor is the medicament of being made by the raw material of following weight portion:
Herba Leonuri 10-30 Cortex Phellodendri 20-40 Cordyceps 1-8
Hide Ganoderma 20-40 Stigma Croci 20-40 Rhizoma Smilacis Glabrae 30-50
Herba Scutellariae Barbatae 20-40 Herba Lobeliae Chinensis 25-40 Hedyotidis Diffusae 30-40
Ramulus et folium taxi cuspidatae 20-40 Radix Sophorae Tonkinensis 10-20 Rhizoma Paridis 25-40
CAOHECHE 20-30 Folium Isatidis 25-40 Radix Glycyrrhizae 20-40.
Be preferably, the medicine of treatment gynecological tumor of the present invention, malignant tumor is the medicament of being made by the raw material of following weight portion:
Herba Leonuri 20-30 Cortex Phellodendri 25-30 Cordyceps 2-5
Hide Ganoderma 30-40 Stigma Croci 25-30 Rhizoma Smilacis Glabrae 35-40
Herba Scutellariae Barbatae 25-30 Herba Lobeliae Chinensis 25-30 Hedyotidis Diffusae 35-40
Ramulus et folium taxi cuspidatae 25-30 Radix Sophorae Tonkinensis 15-20 Rhizoma Paridis 25-30
CAOHECHE 25-30 Folium Isatidis 25-30 Radix Glycyrrhizae 25-30.
In the medicine of treatment gynecological tumor of the present invention, malignant tumor, described medicament is the above a dosage form of any pharmaceutics, is preferably oral liquid.
The preparation method of treatment gynecological tumor of the present invention, malignant tumor medicine, be with above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 5-15 puts into water, through 100 ℃ of steaming and decocting 1.5-3 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
What can select is, the preparation method of treatment gynecological tumor of the present invention, malignant tumor medicine, be through flushing with clean water, section and pulverizing with above-mentioned Chinese medicine, put into extraction pot then, by solid-to-liquid ratio 1: 8-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
What more can select is that the preparation method of treatment gynecological tumor of the present invention, malignant tumor medicine is through flushing with clean water, section and pulverizing with above-mentioned Chinese medicine, put into extraction pot then, by solid-to-liquid ratio 1: 5-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filter time filtrate of winning, extract once more, by solid-to-liquid ratio 1: 3-5 puts into water, through 100 ℃ of steaming and decocting 0.5-1 hours, filter, filtrate for the second time, merge secondary filter liquid, cool off and sealed in 24 hours.
The blood circulation promoting and blood stasis dispelling that treatment gynecological tumor of the present invention, malignant tumor oral liquid and external liquid have, heat-clearing and toxic substances removing is removed scrofula, is festered, the cellulitis toxic swelling, strengthens autoimmune and kills effects such as tumor and cancerous cell.
Consumption: adult: one time 100 milliliters, 6 hours clothes once, children's is cut down according to the circumstance, and is a course of treatment or follows the doctor's advice in 3 months.
External: gynecological tumor perfusion: medicine is expelled to the intravaginal stop got final product twice of every day in 20-30 minute.
Breast tumor: soaked into the hot compress of plaster affected part 20-30 minute with gauze or absorbent cotton.
Logical clinical treatment 1000 many cases gynecological tumors, cyst, muscular tumor, malignant tumor, uterine erosion, vaginitis in a few years, total effective rate 98%, to uterine erosion, the vaginitis better effects if, oral medicine adds external perfusion medicine and thoroughly fully recovered in 7-15 days.
Can disappear in 3 months to slight tumor cyst muscular tumor malignant tumor 1cm-3cm, what 3cm was above also shrinks again.
Clinical effectiveness shows, medicine of the present invention exsomatizes, in the contraction of body uterine smooth muscle obvious inhibitory action arranged animal, can obviously resist the animal that oxytocin causes exsomatize, in body uterine smooth muscle spasm; To the exsomatizing of the hysteromyoma model animal that causes by estrogen, progestogen, obvious inhibitory action is arranged in the contraction of body uterine smooth muscle, can obviously resist the hysteromyoma animal that oxytocin causes exsomatize, in body uterine smooth muscle spasm and leiomyoma of uterus sample hypertrophy, leiomyoma of uterus is obviously reduced, have tangible anti-leiomyoma of uterus effect, reduce hysteromyoma model rat estradiol level; Hysteromyoma rat model uterus is heavily reached the uterus index obvious inhibitory action is also arranged; Obviously the human body immunity improving function suppresses mice S
180The sarcoma growth; Can obviously improve animal uterus mesentery microcirculation.Follow obstacle and " blood stasis " animal has obvious improvement effect to animal due to the high molecular dextran is little, can obviously improve blood flow rate, the blood flow state of animal, make " blood stasis " animal pattern hemorheological property sticking, dense, coagulate state be improved significantly, have good function of promoting blood circulation to disperse blood clots; To suffer from a deficiency of the kidney, the model of spleen deficiency animal has benefiting action, can obviously improve urine xylose excretion rate and serum amyloid enzymatic activity because of " insufficiency of the spleen " model mice due to the eating and drinking without temperance; Can obviously improve ovary weight, uterus weight, pregnancy rate and the average tire Mus number of " suffering from a deficiency of the kidney " model mice due to the testosterone; Has a haemostatic effect preferably to mice docking is hemorrhage; Can obviously shorten clotting time of mice; Swollen and dimethylbenzene induced mice ear is swollen and the rat uterus inflammation has good resist inflammation on repercussive function to rat paw due to the agar; Dichlorodiphenyl Acetate induced mice pain has significant analgesia role.
Medicine of the present invention shows that through clinical use result following advantage is arranged:
1, the present invention selects conventional Chinese medicine for use, and medicine source abundance, each component are that pharmacopeia is contained, meets the pharmaceutical control law regulation.
2, the present invention is an oral liquid, need not decoct medicine mildly bitter flavor, taking convenience.
3, both can use separately, can cooperate chemicotherapy again, can potentiation, can alleviate the chemicotherapy toxicity again, the quality of making the life better prolongs life cycle.
4, inexpensive.
5, treatment and prevent two kinds of effects can be arranged.
Below further specify the present invention by specific embodiment, but embodiment only be used for the explanation, can not limit the scope of the invention.
In the present invention, if not refer in particular to, all parts, amount, percentage ratio are unit of weight, and all raw materials all can be buied from market.
Four, the specific embodiment
Embodiment 1
Take by weighing raw material by following proportioning:
Herba Leonuri 15 grams, Cortex Phellodendri 15 grams, Cordyceps 1 gram is hidden Ganoderma 20 grams,
Stigma Croci 15 grams, Rhizoma Smilacis Glabrae 35 grams, Herba Scutellariae Barbatae 25 grams, Herba Lobeliae Chinensis 20 grams,
Radix Glycyrrhizae 15 grams, Ramulus et folium taxi cuspidatae 25 grams, Radix Sophorae Tonkinensis 15 grams, Rhizoma Paridis 20 grams,
CAOHECHE 20 grams, Folium Isatidis 25 grams, Hedyotidis Diffusae 30 grams.
Extraction pot is put in above-mentioned Chinese medicine is clean through flushing with clean water, section and pulverizing then, puts into water (tap water) at 1: 10 by solid-to-liquid ratio, through 100 ℃ of steaming and decoctings 2 hours, filter, get filter after liquid cools sealed in 24 hours.
Embodiment 2
Take by weighing raw material by following proportioning:
Herba Leonuri 45 grams, Cortex Phellodendri 45 grams, Cordyceps 5 grams are hidden Ganoderma 55 grams,
Stigma Croci 45 grams, Rhizoma Smilacis Glabrae 55 grams, Herba Scutellariae Barbatae 45 grams, Herba Lobeliae Chinensis 40 grams,
Radix Glycyrrhizae 45 grams, Ramulus et folium taxi cuspidatae 45 grams, Radix Sophorae Tonkinensis 30 grams, Rhizoma Paridis 50 grams,
CAOHECHE 30 grams, Folium Isatidis 45 grams, Hedyotidis Diffusae 45 grams.
With above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, put into water at 1: 10 by solid-to-liquid ratio, through 100 ℃ of steaming and decoctings 1.5 hours, filtration, time filtrate of winning, extract once more, put into water at 1: 5 by solid-to-liquid ratio,, get filtrate for the second time through 100 ℃ of steaming and decoctings 1.5 hours, filtration, merge secondary filter liquid, cool off and sealed in 24 hours.
Embodiment 3
Take by weighing raw material by following proportioning:
Herba Leonuri 25 grams, Cortex Phellodendri 25 grams, Cordyceps 2 grams are hidden Ganoderma 35 grams,
Stigma Croci 25 grams, Rhizoma Smilacis Glabrae 35 grams, Herba Scutellariae Barbatae 25 grams, Herba Lobeliae Chinensis 25 grams,
Radix Glycyrrhizae 25 grams, Ramulus et folium taxi cuspidatae 25 grams, Radix Sophorae Tonkinensis 20 grams, Rhizoma Paridis 25 grams,
CAOHECHE 25 grams, Folium Isatidis 25 grams, Hedyotidis Diffusae 35 grams.
Extraction pot is put in above-mentioned Chinese medicine is clean through flushing with clean water, section and pulverizing then, puts into water (tap water) at 1: 8 by solid-to-liquid ratio, through 100 ℃ of steaming and decoctings 2.5 hours, filter, get filter after liquid cools sealed in 24 hours.
Embodiment 4: to the inhibitory action of mice S180 sarcoma
Get Kunming mouse, the S180 tumor liquid 0.25ml/ after the aseptic dilution of right axil subcutaneous injection only, random packet after 24 hours is weighed, intravenously administrable, once a day, continuous seven days, put to death mice next day after the drug withdrawal.Weigh and peel off the subcutaneous tumors piece, claim tumor heavy.Calculate average tumor and heavily reach tumour inhibiting rate.The result shows that each administration group does not all have obvious influence to the mice body weight; Wherein the tumor-inhibiting action of 10ml/kg dosage group is remarkable, compares P＜0.05 with matched group, and average tumour inhibiting rate is 40%.
Embodiment 5: to the influence of mice ehrlich carcinoma and ascitic type liver cancer H22
Kunming mouse abdominal cavity inoculation ehrlich ascites tumor liquid (EAC) or H22 oncocyte 0.5ml/ only, random packet after 24 hours is weighed, intravenously administrable, once a day, continuous seven days.Observe the mice survival rate after the drug withdrawal.The result shows with matched group and compares that high dose group all can significant prolongation mice survival rate (P＜0.05).
Embodiment 6: to the influence of caused by cyclophosphamide leukopenia
Mouse peritoneal injection cyclophosphamide 100mg/kg, once a day, continuous three days.While is oral oral liquid of the present invention from first day, continuous five days.After the last administration 24 hours, get blood and carry out numeration of leukocyte.As a result, obvious decline (P＜0.05) appears in model group leukocyte count by statistics, and the leukopenia phenomenon of 5 milliliters and 10 milliliters dosage groups of oral liquid of the present invention is all not remarkable, and high dose group and model group differences be (P＜0.05) significantly.
Embodiment 7, to the protective effect of acute liver damage due to the carbon tetrachloride
The oral oral liquid of the present invention of Wister rat, after continuous five days, lumbar injection 0.1% carbon tetrachloride 10mg/kg causes the acute liver damage model, measure animal serum ALT, AST level after 24 hours, the result shows: 10mg/kg dosed administration group Serum ALT, AST level obviously reduce (P＜0.05) than normal saline model control group rising amplitude.Through the liver histological pathological observation, the hepatic injury zone has obviously and dwindles.
Claims (8)
1, a kind of medicine for the treatment of gynecological tumor, malignant tumor is characterized in that it is by following weight
The medicament that the raw material of part is made:
Herba Leonuri 10-50 Cortex Phellodendri 10-50 Cordyceps 1-10
Hide Ganoderma 20-60 Stigma Croci 10-50 Rhizoma Smilacis Glabrae 30-60
Herba Scutellariae Barbatae 20-50 Herba Lobeliae Chinensis 20-50 Hedyotidis Diffusae 30-50
Ramulus et folium taxi cuspidatae 20-50 Radix Sophorae Tonkinensis 10-30 Rhizoma Paridis 20-50
CAOHECHE 20-30 Folium Isatidis 20-50 Radix Glycyrrhizae 10-50.
2, the medicine of treatment gynecological tumor according to claim 1, malignant tumor is characterized in that the weight portion of each raw material is:
Herba Leonuri 10-30 Cortex Phellodendri 20-40 Cordyceps 1-8
Hide Ganoderma 20-40 Stigma Croci 20-40 Rhizoma Smilacis Glabrae 30-50
Herba Scutellariae Barbatae 20-40 Herba Lobeliae Chinensis 25-40 Hedyotidis Diffusae 30-40
Ramulus et folium taxi cuspidatae 20-40 Radix Sophorae Tonkinensis 10-20 Rhizoma Paridis 25-40
CAOHECHE 20-30 Folium Isatidis 25-40 Radix Glycyrrhizae 20-40.
3, the medicine of treatment gynecological tumor according to claim 1, malignant tumor is characterized in that the weight portion of each raw material is:
Herba Leonuri 20-30 Cortex Phellodendri 25-30 Cordyceps 2-5
Hide Ganoderma 30-40 Stigma Croci 25-30 Rhizoma Smilacis Glabrae 35-40
Herba Scutellariae Barbatae 25-30 Herba Lobeliae Chinensis 25-30 Hedyotidis Diffusae 35-40
Ramulus et folium taxi cuspidatae 25-30 Radix Sophorae Tonkinensis 15-20 Rhizoma Paridis 25-30
CAOHECHE 25-30 Folium Isatidis 25-30 Radix Glycyrrhizae 25-30.
4,, it is characterized in that described medicament is the above a dosage form of any pharmaceutics according to the medicine of the described treatment gynecological tumor of one of claim 1-3, malignant tumor.
5, the medicine of treatment gynecological tumor according to claim 4, malignant tumor is characterized in that described dosage form is an oral liquid.
6, according to the preparation method of the medicine of the described treatment gynecological tumor of one of claim 1-5, malignant tumor, it is characterized in that above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 5-15 puts into water, through 100 ℃ of steaming and decocting 1.5-3 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
7, the preparation method of the medicine of treatment gynecological tumor according to claim 6, malignant tumor, it is characterized in that above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 8-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
8, the preparation method of the medicine of treatment gynecological tumor according to claim 6, malignant tumor, it is characterized in that just above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, puts into extraction pot then, by solid-to-liquid ratio 1: 5-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filtration, win time filtrate extracts once more, and by solid-to-liquid ratio 1: 3-5 puts into water, through 100 ℃ of steaming and decocting 0.5-1 hours, filtration, filtrate for the second time, merge secondary filter liquid, cool off and sealed in 24 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101299186A CN101088541B (en) | 2007-07-20 | 2007-07-20 | Medicine for treating women's tumors and malignant tumors and its prepn proces |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101299186A CN101088541B (en) | 2007-07-20 | 2007-07-20 | Medicine for treating women's tumors and malignant tumors and its prepn proces |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101088541A true CN101088541A (en) | 2007-12-19 |
| CN101088541B CN101088541B (en) | 2010-04-07 |
Family
ID=38942142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101299186A Active CN101088541B (en) | 2007-07-20 | 2007-07-20 | Medicine for treating women's tumors and malignant tumors and its prepn proces |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101088541B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656430A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Traditional Chinese medicine for treating female hysteromyoma |
| CN105663351A (en) * | 2016-04-08 | 2016-06-15 | 张伟 | Chinese herbal preparation for treating malignant tumors |
| CN106492012A (en) * | 2016-11-07 | 2017-03-15 | 福建万亿店中店电子商务有限责任公司 | A kind of antitumor Chinese herbal medicine extract and preparation method thereof |
| CN108042738A (en) * | 2018-01-18 | 2018-05-18 | 孙桂霞 | A kind of Chinese medicine and its preparation process for treating gynecological tumor |
| CN108992550A (en) * | 2018-10-10 | 2018-12-14 | 广东云瑶生物医药科技有限公司 | A kind of preparation method and applications of the Chinese medicinal compound for tumor of breast disease of preventing epidemic |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1290562C (en) * | 2004-10-29 | 2006-12-20 | 李永胜 | Chinese traditional medicine composition for resisting malignant tumor (cancer) |
-
2007
- 2007-07-20 CN CN2007101299186A patent/CN101088541B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656430A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Traditional Chinese medicine for treating female hysteromyoma |
| CN103656430B (en) * | 2013-12-11 | 2015-09-23 | 山东中大药业有限公司 | A kind of Chinese medicine for the treatment of female myoma of uterus |
| CN105663351A (en) * | 2016-04-08 | 2016-06-15 | 张伟 | Chinese herbal preparation for treating malignant tumors |
| CN106492012A (en) * | 2016-11-07 | 2017-03-15 | 福建万亿店中店电子商务有限责任公司 | A kind of antitumor Chinese herbal medicine extract and preparation method thereof |
| CN108042738A (en) * | 2018-01-18 | 2018-05-18 | 孙桂霞 | A kind of Chinese medicine and its preparation process for treating gynecological tumor |
| CN108992550A (en) * | 2018-10-10 | 2018-12-14 | 广东云瑶生物医药科技有限公司 | A kind of preparation method and applications of the Chinese medicinal compound for tumor of breast disease of preventing epidemic |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101088541B (en) | 2010-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105343625A (en) | Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN101433654B (en) | Chinese medicine preparation for treating women's chronic pelvic inflammatory disease and preparation method thereof | |
| CN102058715B (en) | Chinese medicine preparation for treating chronic prostatitis and preparation method thereof | |
| CN101088541B (en) | Medicine for treating women's tumors and malignant tumors and its prepn proces | |
| CN103041208A (en) | Chinese herbal preparation for treating climacteric syndrome of women, and preparation method thereof | |
| CN105381352A (en) | Topical traditional Chinese medicine lotion for treating gynecological inflammation | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN103041262B (en) | Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof | |
| CN100525798C (en) | Medicine for treating women's inflammation and its preparing method | |
| CN103041247B (en) | Traditional Chinese medicine suppository for curing colpitis and preparation method thereof | |
| CN104587302A (en) | Traditional Chinese medicine preparation for treating acute appendicitis | |
| CN104524106A (en) | Traditional Chinese medicine preparation for treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN101637552B (en) | Chinese medicine compound for controlling chronic pelvic inflammation | |
| CN103169883A (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN102526620B (en) | Traditional Chinese medicinal composition for treating gynecological inflammation and application of same | |
| CN102309651A (en) | New use of compound traditional Chinese medicine | |
| CN105125792A (en) | Traditional Chinese medicinal decoction for treating female mastitis and preparation method of decoction | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103127460B (en) | Traditional Chinese medicine composition for curing gynecologic inflammation and preparation method thereof | |
| CN101850101B (en) | Chinese medicinal composition for treating metrostaxis and preparation method thereof | |
| CN105055875A (en) | Traditional Chinese medicine used for treating cold-dampness heat-type endometritis, and preparation method thereof | |
| CN102743686A (en) | Pelvic inflammation-clearing capsule | |
| CN106110204A (en) | A kind of Herba Taraxaci oral liquid improving immunity and preparation method thereof | |
| CN105560994A (en) | Traditional Chinese medicine composition for treating prolapse of uterus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |